抽象的

Aurora Kinase Inhibitors in Target Specific Cancer Treatment

Yusuf Tutar

Targeted therapy is one of the major treatment modalities in medical oncology. Targeted therapy aims to inhibit oncogenic pathways by interfering with target biomolecules. For this reason drug designers have focused on investigation of new targets in order to develop efficient cancer drugs [1]. Aurora kinases are important members of the serine/threonine kinases and three forms of the Aurora kinases have been identified: Aurora-A, Aurora-B, and Aurora-C in human. Especially, Aurora-A and Aurora-B play key roles in mitotic checkpoint activation, chromosome orientation, cell proliferation, cytokinesis, and mitotic spindle formation in cells. Alteration of their expression level is related with mitotic errors and aberrant expression of these enzymes may trigger multiple oncogenic pathways. Therefore, Aurora-A and Aurora-B kinases have been potential targets in new generation cancer drug development research.

索引于

化学文摘社 (CAS)
哥白尼索引
打开 J 门
学术钥匙
研究圣经
引用因子
电子期刊图书馆
参考搜索
哈姆达大学
学者指导
国际创新期刊影响因子(IIJIF)
国际组织研究所 (I2OR)
宇宙
日内瓦医学教育与研究基金会
秘密搜索引擎实验室

查看更多